manufacturers over menus of formulary-contingent rebate payments and then selects a formulary. We then estimate how formulary … predictions align with aggregate rebate data, and we find that allowing a PBM to place branded drugs on preferred and non …-preferred tiers can substantially increase negotiated rebate payments …

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …

study assesses the impact of a negotiation situation for lifeextending pharmaceuticals on societal outcomes. Of interest …Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health … the pricing mechanics, but also the process of value assessment and price negotiation are subject to reform demands. This …